# A systematic review and meta-analysis of the prevalence of psoriasis in patients living with HIV

## TL;DR

This study finds that about 2% of people with HIV have psoriasis, with a slight decrease in prevalence over time.

## Contribution

The study provides the first comprehensive meta-analysis of psoriasis prevalence in HIV-positive individuals across different time periods and regions.

## Key findings

- The overall prevalence of psoriasis in HIV-positive individuals is 2.0%.
- Prevalence was higher in the 1984–1994 period (5.0%) compared to 2000–2022 (1.0%).
- Publication bias was identified, but results remained stable after sensitivity analysis.

## Abstract

•Estimate psoriasis prevalence in HIV-positive individuals via meta-analysis.•Analyze trends over time (1984–1994 vs. 2000–2022) and by regional latitude.•Identify publication bias; confirm result stability through sensitivity analysis.•Guide health resource allocation and policy for HIV-associated psoriasis.

Estimate psoriasis prevalence in HIV-positive individuals via meta-analysis.

Analyze trends over time (1984–1994 vs. 2000–2022) and by regional latitude.

Identify publication bias; confirm result stability through sensitivity analysis.

Guide health resource allocation and policy for HIV-associated psoriasis.

This study aimed to perform a comprehensive examination of the prevalence of psoriasis in people with HIV, aiming to offer valuable evidence for informed resource allocation and policy formulation.

Methods: The authors systematically gathered literature on psoriasis prevalence among those with HIV from multiple sources. These sources comprise databases such as CNKI, VIP, Wanfang Database, PubMed, Cochrane Library, and EMBASE up to June 30, 2024. Additionally, manual searches were conducted to supplement the data collection process. Two independent researchers carried out literature screening, relevant data extraction, and assessment of potential bias. Meta-analysis was conducted with RevMan 5.3 software. Results Fifteen investigations were incorporated, involving 130,032 individuals with HIV. The meta-analysis of these fifteen pieces showed that the occurrence rate of psoriasis in those infected with HIV was 2.0 % (95 % CI: 2.0 %–2.0 %). Divide the survey years into two subgroups: 2000–2022 years and 1984–1994 years, with prevalence rates of 1.00 % (1.00 %–1.00 %) and 5.00 % (3.00 %–7.00 %), respectively. According to regional latitude, it is divided into two subgroups: latitude ≥ 30° N/S and latitude ˂ 30° N/S, with prevalence rates of 2.0 % (1.0 %–2.0 %) and 3.0 % (2.0 %–5.0 %), respectively. The results of the funnel plot, Begg's test (Z = 0.038, p = 0.856), and Egger's test (t = 4.68, p ˂ 0.001) showed publication bias in the literature. Sensitivity analysis revealed no substantial difference between the analysis of the FEM and that of the REM for psoriasis prevalence, suggesting that the stability of the findings in this study is satisfactory. Conclusion The incidence of psoriasis in HIV-infected individuals has shown a slight downward trend, and the differences are not significant in different latitude regions.